Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
1.040
+0.055 (5.62%)
At close: Nov 22, 2024, 4:00 PM
0.993
-0.047 (-4.53%)
After-hours: Nov 22, 2024, 6:36 PM EST
Jaguar Health Employees
Jaguar Health had 49 employees as of December 31, 2023. The number of employees decreased by 11 or -18.33% compared to the previous year.
Employees
49
Change (1Y)
-11
Growth (1Y)
-18.33%
Revenue / Employee
$213,878
Profits / Employee
-$770,245
Market Cap
9.61M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Evogene | 142 |
RedHill Biopharma | 53 |
Vincerx Pharma | 42 |
NeuroMetrix | 26 |
Soligenix | 15 |
Onconetix | 12 |
BioRestorative Therapies | 11 |
JAGX News
- 19 hours ago - Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs - Accesswire
- 3 days ago - Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe” - Accesswire
- 7 days ago - Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Jaguar Health Reports Third Quarter 2024 Financial Results - Accesswire
- 11 days ago - Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates - Accesswire
- 16 days ago - FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs - Accesswire
- 18 days ago - Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS) - Accesswire
- 24 days ago - Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting - Accesswire